Method of selection of an IRE1-inhibitor therapy for patient suffering from cancer
View Patent ↗The present invention relates to a method of treatment and method of therapy selection for patient suffering from cancer. The inventors provide the first demonstration of a dual role of IRE1 downstream signaling in cancer. Indeed, the inventors demonstrate that the modulation of IRE1 signaling characteristics in GBM cells controls tumor aggressiveness. Furthermore, the inventors provide evidence supporting a novel concept where IRE-downstream signals play combined/integrated roles in cancer development, where XBP1s provides pro-tumoral signals, whereas RIDD of mRNA and miR17 rather elicits anti-tumoral features. Their data, obtained using established cell lines, patient tumor samples and primary GBM lines, depict a complex scenario where IRE1 signaling orchestrates distinct aspects of GBM biology. In particular, the invention relates to a method for predicting whether a subject will be eligible to a treatment with an IRE1 RNase inhibitor.
1. A method for predicting whether a human subject will be eligible for treatment with an IRE1 RNase inhibitor and treating said subject comprising:
i) determining an expression level of ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2, ZNF804A, ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and/or TMEM255A in a tumor sample obtained from the subject,
ii) comparing the expression level of each gene determined at step i) with its respective predetermined reference level,
iii) concluding that the subject is eligible for treatment with an inhibitor of IRE1 RNase when the expression level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and/or ZNF804A is lower than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and/or TMEM255A is higher than its predetermined reference level,
or concluding that the subject is eligible for treatment with an inhibitor of IRE1 RNase when the expression level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and/or ZNF804A is higher than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and/or TMEM255A is lower than its predetermined reference level, and
iv) administering to the subject a therapeutically effective amount of an IRE1 RNase inhibitor when the subject is eligible for treatment with an IRE1 RNase inhibitor.
2. The method of claim 1 , wherein the subject suffers from cancer.
3. The method of claim 1 , wherein the subject suffers from neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli ; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; non encapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous; adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; and roblastoma, malignant; Sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malign melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brennertumor, malignant; phyllodestumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; strumaovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblasticodontosarcoma; ameloblastoma, malignant; ameloblasticfibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocyticleukemia; mast cell leukemia; megakaryoblasticleukemia; myeloid sarcoma; or hairy cell leukemia.
4. The method of claim 1 , wherein the subject suffers from bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, esophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, or uterine cancer.
5. The method of claim 1 , wherein the subject suffers from glioblastoma, melanoma or colorectal cancer.